Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 30

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 30
---
 was mainly due to the reduction in general and administrative expenses and Kadimastem’s efficiency measures during the reporting period which included a reduction in research and development expenses. Net Cash Used in Investing Activities Net cash received in investing activities for the six months ended June 30, 2025, was $0, reflecting a decrease of $30,319 compared to cash used of $30,319 for six months ended June 30, 2024. The change was mainly attributed to changes in pledged cash. Net cash received from investing activities for the year ended December 31, 2024, was $161,394, reflecting an increase of $70,844 compared to cash from investing activities of $90,550 for the year ended December 31, 2023. The change was mainly attributed to purchases of fixed assets and changes in pledged cash. Net Cash Provided by Financing Activities Net cash provided by financing activities for the six months ended June, 30 2025, amounted to $277,932, representing an increase of $27,526 compared to $250,406 for the six months ended June 30, 2024. This increase was primarily due to .a loan received from Prof. Michel Revel, Kadimastem’s Chief Scientific Officer, director and significant shareholder of Kadimastem in the amount of $269 thousand, compared to loan of $458 thousand received from shareholders offset by repayment of lease liability in amount of $208 thousand during the first six months of 2024. Net cash provided by financing activities for the year ended December 31, 2024, amounted to $89,270, representing a decrease of $2,311,803 compared to $2,401,073 for the year ended December 31, 2023. This decrease was primarily due to capital raised by Kadimastem and proceeds from a convertible loan during the year ended December 31, 2023. 17 During the six months ended June 30, 2025, the cash flow from financing activities included the receipt of a convertible loan from Kadimastem’s shareholders, in the amount of $278,000. Financing Developments Recent Developments (January 1, 2025 to the date of this proxy statement/prospectus): On April 14, 2025, Kadimastem announced that, Mr. Julien Ruggieri, a significant shareholder of Kadimastem, provided Kadimastem with a written notice of his decision to convert $500,000